Background: Nicotine acethylcholine receptors (nAChRs) play critical roles in cognitive processes, neuroprotection, and inflammation. Results: According to their substituents, 1,3-diphenylpropan-1-one derivatives act as α7 nAChRs negative allosteric modulators (OMe) or Type I positive allosteric modulators (PAMs, OH). Compounds 7 and 31 were the most effective (989 and 666% enhancement of AChinduced currents) and potent (EC 50 : 12.9 and 6.85 µM) PAMs. They exhibited strong radical scavenging values. Compound 31, selective over other neuronal nAChR subtypes and with acceptable pharmacokinetic profile, showed antinociceptive effects in a model of inflammatory pain. Conclusions: Compound 31 is a novel, potent and selective α7 nAChR PAM, displaying antioxidant and analgesic activities. The 1,3-diphenylpropan-1-one scaffold could be the base toward more advanced PAMs for the treatment of nAChR-mediated diseases.
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated channels widely expressed in the nervous system, and involved in a variety of disorders, including psychiatric, neurodegenerative and antiinflammatory processes [1] [2] [3] . Among them, the neuronal α7 receptor subtype (α7 nAChRs) has attracted considerable interest as a potential target for therapeutic intervention in schizophrenia, Alzheimer's disease and different pain conditions [4, 5] . Most of the compounds described as modulators of these channels are competitive agonists or antagonists that interact at the orthosteric binding site of the endogenous ligand, acetylcholine [2, 6] . However, recent efforts have been focused on exploring the pharmacological diversity of compounds able to interact with the receptor at allosteric binding sites [7, 8] . These can be allosteric agonists, positive allosteric modulators (PAMs), which potentiate the agonist-evoked responses without activating or desensitizing the receptor in a direct way, negative allosteric modulators (NAMs), able to reduce the effects of the orthosteric ligand, and silent allosteric modulators (SAMs) that bind to the allosteric site without producing a change in orthosteric binding or efficacy [9] . There are two types of PAMs, differing in their effects on receptor desensitization. Type I PAMs have little or no effect on the rate of agonist-induced desensitization, while Type II cause a noteworthy duration of channel opening, due to delayed desensitization [7] .
The search for allosteric modulators of α7 nAChRs is of great interest because they could selectively regulate this subtype versus other nicotinic receptors, and even homologue serotonine receptors (5-HT 3 ), thus avoiding many of the secondary effects associated to ligands that target the highly conserved acetylcholine binding site [8] . Despite the limited number of compounds described as α7 nAChR PAMs, several of them have advanced towards clinical development [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . Within the families of α7 nAChR allosteric modulators, a series of cyclopentatetrahydroquinoline-8-sulfonamide derivatives is worth mentioning, since they showed different pharmacological properties depending on the nature, number and position of certain substituents [9, 24] . For instance, minor chemical changes like the configuration, the interchange of halogens, or different patterns of methyl substitution in the aromatic moiety at position 2 of the tetrahydroisoquinoline ring resulted in either PAMs (Type I or II), NAMs, SAMs, or allosteric agonists [9, 24] .
Upon screening of a heterogenous collection of small natural products, we identified a polyhydroxy substituted chalcone, Isoliquiritigenin (1, Figure 1) , as a selective Type I PAM of α7 nAChRs [25] . The screening of a collection of one hundred commercial chalcones led to the identification of its regioisomer 2, as a potent and selective α7 nAChR Type II PAM. This compound was taken as a hit for the preparation of a series of polysubstituted chalcone analogues, aimed at improving its pharmacodynamic profile. Modifications on the number, position or nature of the substituents, led to several analogues with interesting properties as α7 nAChRs PAMs. One of the new prepared analogues, compound 3, exhibited much higher potency than the model parent compound 2, and a similar increase in the peak of ACh-evoked currents mediated by human α7 nAChRs expressed in Xenopus oocytes [25] . In addition, compound 3 displayed neuroprotective activities in vitro, and antinociceptive effects in a mechanical hyperalgesia in vivo test. Although this compound showed low toxicity, the conjugated double bond can be seen as a drug structural alert, because of its high chemical reactivity towards oxidation and potential capacity as Michael acceptor versus nucleophiles. Therefore, analogues of 3 lacking the α,β-unsaturated carbonyl linker could serve to mitigate the risk of potential idiosyncratic drug toxicity [26] .
To this aim, and to further investigate the potentiality of this series of α7 nAChRs PAMs, in this contribution we explore the reduction of the double bond or the carbonyl group that form the linker chain joining the two aromatic rings in this family of chalcones. The transformation of the double bond into a pyrrole ring was also performed. While the methoxy-substituted 1,3-diphenylpropa-1-one derivatives behave as α7 nAChRs NAMs, the hydroxyl analogues showed, in general, a typical Type I PAM profile. One of these derivatives, the reduced analogue of chalcone 2 was shown to significantly inhibit thermal hyperalgesia in vivo while the corresponding to chalcone 3 did not, a different behavior that can be explained in terms of their dissimilar pharmacokinetic properties. In addition, the hydroxy 1,3-diphenylpropa-1-ones, as well as chalcone 3, show remarkable antioxidant properties.
Results & discussion
Chemistry First, we were interested in the reduction of the double bond of the spacer chain, keeping intact the carbonyl group. Starting from methoxy chalcone 4, attempts to hydrogenate it over Pd/C were not completely satisfactory, since the main reaction product was the alcohol 5, that result from the concomitant hydrogenation of the double bond and the carbonyl group, while the desired product 6 was the minor component of the reaction. Preparation of 6 was finally achieved in good yield by performing the Pd/C hydrogenation in the presence of diphenyl sulfide, a catalyst poison that selectively hydrogenates olefin and acetylene functionalities without hydrogenolysis of aromatic carbonyls [27] . Polyhydroxylated compound 7 was obtained from the methoxy propan-1-one analogue 6 by treatment with BBr 3 in Cl 2 CH 2 [28] , the same procedure followed in the preparation of the hydroxychalcone series (Figure 2) . However, a similar treatment failed in the case of compound 5 that decomposed under these reaction conditions.
The good α7 nAChR potentiation value found for compound 7, as we will comment later, prompted us to prepare the propan-1-one analogues of the rest of our previously described hydroxylated chalcones [25] . Thus, hydrogenation of the double bond of methoxylated chalcones 8-12 using the Pd-C/Ph 2 S system led to propan-1-ones 13-17 in good to excellent yield. Deprotection of the methoxy groups of 13-15 afforded the expected hydroxy derivatives 18-20, while the treatment of compounds 16 and 17 with BBr 3 in DCM gave untreatable complex mixtures (Figure 3) .
Alternatively, compounds 24-26, monohydroxylated in ring A, were obtained by direct hydrogenation of the corresponding hydroxyl-chalcones 21-23, previously prepared by us (Figure 4) [25] .
For the synthesis of derivatives monosubstituted in ring B, we first prepared monohydroxy dimethoxychalcones 27 and 28, by condensation of commercial 2,5-dimethoxyacetophenone and the corresponding 2-hydroxy and 4-hydroxybenzaldehydes. The procedure involved then hydrogenation to propan-1-ones 29 and 30, and subsequent deprotection of the methoxy groups. Compound 31, the reduced analogue of chalcone 2, was obtained in this way, but deprotection of MeOgroups of 29 did not work, recovering the starting material unaltered, probably because of steric hindrance around the 2'-OMe group. (Figure 5) .
On the other hand, attempts to selectively reduce the carbonyl group, keeping the double bond unaltered, were unsuccessful. Several assays using BH 4 Na, alone or in the presence of CeCl 3 , following the methodology described by Luche, [29] led to complex mixtures, difficult to handle, due to partial reduction of the double bond and formation of unidentified minoritary byproducts that difficulted the purification and lowered the yield of the desired compound.
The introduction of heterocyclic rings at the linker was also contemplated, taking profit of the reactivity of the conjugated double bond. Moreover, the resulting products will have a certain analogy with some thiazole and pyrrol derivatives described as PAMs of the α7 nicotinic receptor [15, 30] . Several attempts to prepare the pyrazol-containing compound by reaction of the chalcone with trimethyl silyl diazomethane failed. However, the preparation of pyrrol derivative 32 was achieved starting from 3, through the 1,3-dipolar cycloaddition with tosylmethyl isocyanide (TOSMIC) in the presence of sodium hydride as base [31] . Further deprotection with BBr 3 led to the final hydroxy derivative 33 ( Figure 6 ).
Biological evaluation  Electrophysiological Studies
Synthesized compounds were evaluated as modulators of α7 nAChRs expressed in Xenopus oocytes. For this purpose, each compound (10 μM) was co-applied with ACh (200 μM), and the resulting currents were compared to those induced by ACh alone. As shown in Table 1 , the precursor derivatives, with methoxy groups, induced in general current percentage values below 100% (which is the control value with 200 µM ACh alone). Therefore, these compounds act as inhibitors of α7 nAChRs. Maximal inhibition was obtained with compounds 6 (15% of current observed with ACh alone), 16 (26%) and 13 (29%). This behavior was also observed for the related tetrasubstituted methoxy-chalcone 4, although the inhibitory capacity was slightly lower (35%). Reduced analogues 14 and 15, with three OMe groups in ring A and one or two in ring B were poorer inhibitors. Derivatives bearing two OMe groups in ring A, and one OH moiety at ring B (29 and 30) were very weak inhibitors . Finally, pyrrole derivative 32 showed only marginal inhibitory ability.
Experiments to determine if these compounds behave as competitive antagonist, competing with ACh for its binding site, or as negative allosteric modulators of the α7 channels were performed. Figure 7 features a comparison between compound 6, which is the most potent inhibitor, and its chalcone analogue compound 4. When either of the twowas applied to oocytes expressing human α7 nAChRs, a substantial decrease was observed in AChevoked ionic currents (Figure 7c & d) . Their decay, however, was similar to control currents, so that changes in kinetics were not apparent. Concentration-response relationships (Figure 7e & f) showed that compound 6 was about 4-fold more potent than compound 4 (IC 50 for compounds 6 and 4 was 2.1 and 9.1 μM, respectively). ACh concentration-response relationships were displaced to the right in the presence of compounds 4 and 6 (Figure 7g & h) (EC 50 for ACh was 176 μM in control conditions and 2067 μM and 536 μM in the presence of compounds 4 and 6, respectively). Although these data do not rule out a competitive mechanism, that would need a Schild analysis, negative allosterism is the most probable mechanism given the compounds' structures and the positive allosteric mechanism of structurally similar compounds 7 and 31 (see below).
Besides, effects of the hydroxy substituted compounds in α7 nAChR currents are shown in Table 2 . In general, all propan-1-one derivatives were less effective in potentiating the ACh-evoked currents than the corresponding chalcone analogues. In this series, the most efficient α7 nAChR PAMs were 7 and 31, the propan-1-one analogues corresponding to the most powerful chalcone derivatives 3 and 2 respectively. Compounds 7 and 31 at 10 μM were able to enhance the current induced by ACh by 989 and 666%, respectively. Therefore, the reduction of the double bond of the chalcone linker resulted in about 2-3 fold less efficient PAMs. Table 3 ), but 31 was about two-fold less potent than 7, as deduced from their potentiating EC 50 : 12.9 μM and 6.85 μM for 31 and 7, respectively (Figure 8e & f and Table 3 ). These potencies are comparable to those observed in similar conditions for other PAMs, such as PNU-120596 (EC 50 3.8-5.8 μM) [10, 32] , TQS (5.5 μM) [32] , and A-86774 (1.1 μM) [15] . However, maximum efficacy is probably much higher in our compounds because enhancements were not only larger than the 4 to 6-fold maximal potentiation reported in [32] , but were also obtained with a higher ACh concentration (0.2 vs. 0.1 mM), which would have underestimated the potentiating effect. Additionally, comparing the data of I max and EC 50 of propanone 7 with that of the parent compound 3, a slight decrease of efficacy and potency was observed, while compound 31 displayed lower efficacy but a small increase in potency when compared to chalcone 2 ( Table 3) .
The potentiating effect was not much dependent on ACh concentration. As shown in Figure 8g & h, when 10 μM of compound 31 or 5 μM of compound 7 (concentrations close to the corresponding EC 50 ) were co-applied with ACh, the resulting ACh concentration-response relationships were shifted to the left, as the ACh EC 50 values decreased from 176 μM (control) to 38.3 μM and 71.3 μM in the presence of 31 and 7, respectively.
Compounds 7 and 31 were also evaluated for their activity at α3β4 and α4β2 nAChRs expressed in Xenopus oocytes, as these two receptor subtypes represent typical representatives of peripheral and central heteromeric receptors, respectively. While the tetrahydroxy derivative 7 was able to inhibit the currents induced by ACh at these heteromeric channels (up to 44%), the trihydroxy analogue 31 did not exert any action at these receptors (see SD, Table S1 ). Therefore, 31 is highly selective towards α7 nAChRs.
Given the importance of OH groups for our compounds to behave as α7 nAChR PAMs, initially we would not have expected activity for the OMe analogues on this receptor, but surprisingly they worked as NAMs. Changes of PAMs to other types of allosteric modulators have been previously reported for another family of α7 nAChR modulators, upon truly very minor chemical modification, like the exchange of halogens, S to R configuration change, and modification of the number and/or positions of methyl substituents [9, 24] .
 Analgesic Activity Agonists and positive allosteric modulators of α7 nAChRs display antinociceptive and anti-inflammatory properties in different animal models [7, 18] . For instance, PNU-120596 induced analgesic activity by its own or combined with choline in the formalin pain test, and showed anti-allodynic effects in the CCI neuropathic pain model [33] [34] [35] . On the other hand, it is reported that different dietary polyphenols, like chlorogenic acid (CGA), resveratrol and quercetin derivatives, have antinociceptive effects on acute, inflammatory and neuropathic pain models [36] [37] [38] , although their mechanisms of action are not totally understood.
We have previously studied PNU-120596 and chalcone 3 (10 mg/Kg) for the reduction of thermal and mechanical hyperalgesia resulting from inflammation induced by complete Freund's adjuvant (CFA). Both showed antinociceptive effects in the mechanical hyperalgesia test, and lacked significant activity in the thermal assay [25] . Main peak of activity was at 2h for PNU-120596 and at 30 min for chalcone 3, probably due to different pharmacokinetic drug clearance.
When compounds 7 and 31 were tested for their antihyperalgesic properties in the above mentioned mechanical test, very different results were obtained. While no signs of antinociceptive activity were observed for tetrahydroxy derivative 7 (Figure 9 , left), the trihydroxy analogue 31 (Figure 9 , right) exhibited analgesic activity comparable to that demonstrated by PNU-120596 [25] . Compound 31 displayed significant activity at 1 h and the maximum peak at 2 h after the injection, like PNU derivative. The differences between 7 and 31 in in vivo experiments could be accounted for by distinct mechanisms, including the lack of selectivivity of the former, the stronger effect on desensitization of the latter, and their different pharmacokinetic profiles, as commented in the next section.
 Physicochemical Properties and Preliminary In Vitro ADME (AdministrationDistribution-Metabolism-Excretion) Profile. To get an insight on the potential of this series of compounds for further progress in the drug development process, we characterized their pharmacokinetic (PK) features. Some theoretical and experimental PK parameters of propan-1-one analogues 7 and 31, showing the best α7 nACh activity, are shown in Table 4 , and compared with those of the parent chalcone 3. They include physicochemical properties such as molecular weight (MW), calculated lipophilicity (CLogP), and polar surface area (PSA). In addition, a short in vitro ADME profile for the three compounds was performed, including solubility in simulated fluids, ability to bind to plasma proteins, permeability in Caco-2 cells, and metabolism in human liver microsomes.
Taking into account the calculated physicochemical parameters, the low MW (<300 Da) and the calculated CLogP (2.51-2.71) and PSA (77-97) values for the three compounds were suggestive of probable good oral absorption ( Table 4) .
From the in vitro PK data, compound 3 showed quite limited aqueous solubility, especially at pH >7, but propan-1-ones 7 and 31 are more soluble in the three simulated fluids. While 3 is a totally planar molecule that could stack to form aggregates, the reduction of the double bond necessarily break the planarity, thus increasing solubility in 7 and 31. The three compounds bound very strongly to plasma proteins (> 95%), but the experimental permeability in Caco-2 cells was clearly different among them. The values for compounds 3 and 7 indicated a moderate-to-low permeation and a certain probability of efflux. For compound 3, this low permeability could be due, at least in part, to the quite limited aqueous solubility in the different fluids, but other factors should be responsible for the poor value of 7. Probably, the low permeability of compound 7 is the main responsible of its inactivity in the analgesia in vivo test. However, the permeability increased by 6-and 10-fold in the case of the in vivo active compound 31 with respect to 3 and 7, respectively. The lower molecular weight and the PSA value could be behind the higher permeability. In relation to microsomal metabolic labilities, all compounds showed acceptable to good half-life values for an initial lead compound, but their apparent intrinsic clearances were quite high, indicating low hepatic metabolic stability. The 19 min difference in t 1/2 between 3 and 7 indicates that the chalcone double bond is a labile point for metabolic modification, probably through oxidation. Similarly, the lower half-life of 31, lacking the 2-OH group, when compared to 7 (t 1/2 = -24 min) is an indicative of another metabolically active position. All these information could help us in designing further modifications around the structure of compounds 3, 7 and 31 to improve essential PK properties, while maintaining the potency as α7 nAChR PAMs.
 Antioxidant Capacity
The antioxidant properties of many hydroxy-containing natural products are well documented, and it is suspected that this property is behind many of their beneficial effects on health, expanding from neuroprotective and antiinflammatory effects to the prevention of cancer and cardiovascular diseases [39] [40] [41] [42] . Hydroxyl groups of phenols are one of the key moieties to enhance antioxidant activity due to its easy conversion to phenoxy radicals through a hydrogen transfer mechanism [43] . As our allosteric α7 nACh modulators bear three or four hydroxy groups on their structures, we decided to evaluate their possible antioxidant activity. For this purpose, the oxygen radical scavenging capacity of compounds 3, 7 and 31 was measured by the ORAC assay ( Table 5 ). All compounds exhibited strong radical scavenging activities, similar or even higher than those described for well-known flavonoids [44, 45] . According to these results, the antioxidant activity of our compounds is dependent on the number of OH groups in the molecule and on the linker joining the phenyl rings. Thus, for tetrahydroxy derivatives, the oxygen radical scavenging capacity is higher for the reduced compound 7 than for the alkene-counterpart 3. Between reduced compounds, the ORAC value is better for the tetra-than for the trihydroxy derivative (7 > 31).
The combination of antioxidant properties and allosteric potentiation of α7 nAChRs in a single molecule is a new trend in the therapy of Alzheimer disease (AD). This occurs in the case of galantamine [46] , a marketed drug for AD treatment, and epigallocatechin gallate that acts as a neuroprotecting agent against Aβ toxicity [47] . Therefore, the opportunity of using our compounds to tackle AD on multiple fronts is open.
Experimental
General synthetic and analytical chemistry methods, as well as the characterization of new compounds not described in this section are included in the Supporting Information.
 Chemistry
 General procedure for the preparation of 1,3-diphenyl-1-propanones: To a solution of the corresponding chalcone (0.30 mmol) in MeOH (30 mL) and diphenylsulfide (0.003 mmol), Pd/C 10% (10% weight) was added. After hydrogenation, at room temperature and 20 psi during 24h, the catalyst was filtered off, the solvent evaporated under vacuum, and the residue purified by flash chromatography as indicated.  General procedure for the deprotection of methoxy substituted compounds: To a previously cooled solution (0°C) of the corresponding methoxy substituted compound (0.60 mmol) in dried DCM (15 mL), a 1M solution of BBr 3 in DCM (2 equiv for each MeO-group plus 2 more equiv for every group containing a potentially basic N or O) was slowly added under Ar atmosphere. After stirring 24-48 h at room temperature under Ar, H 2 O was added to the reaction mixture. The solid precipitate formed was separated by filtration, and washed with H 2 O and DCM. In the cases when no precipitate was observed, the product was extracted with EtOAc. The organic extracts were washed with H 2 O and brine, dried over Na 2 SO 4 and then evaporated. The crude product was purified as indicated in each case. 
1-(2',5'-Dimethoxyphenyl)-3-(2,4-dimethoxyphenyl)-1-propanone (6)
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1-(2',5'-Dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-1-propanone (7)
Reddish
1-(2',5'-dihydroxyphenyl)-3-(4-hydroxyphenyl)-1-propanone (31)
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 Biological procedures
 Oocyte Expression and Electrophysiological Studies. All human nAChR cDNAs were cloned in derivatives of the pSP64T vector containing part of the pBluescript polylinker. Capped mRNA was synthesized in vitro using SP6 RNA polymerase, the mMESSAGE-mMACHINE kit from Ambion (Thermo Fisher Scientific, Madrid, Spain) and the pSP64T derivatives mentioned above. Defoliculated Xenopus laevis oocytes were injected with 5 ng of each subunit cRNA in 50 nL of sterile water. All experiments were performed within 2-3 days after cRNA injection. Unless otherwise specified, compounds were pre-applied in the bath for 2 min and then coapplied with ACh through a pipette held very close to the oocyte for fast application. Functional expression of each receptor was estimated as the peak ionic current evoked by 0.6 s application of 0.2 mM ACh at -80 mV. All experiments were performed at 22°C. Current records were measured with Clampfit 10.0 (MDS Analytical Technologies, Sunnyvale, CA, USA). Normalized peak currents were obtained by dividing the maximum value of the current obtained in the presence of compound by the maximum value of the current obtained in control conditions. Dose-response curves for the peak current obtained with ACh were fitted to the Hill equation: Normalized current = I max /(1 + (EC 50 CFA emulsion (1:1 oil/saline, 0.5 mg/mL) was injected into the plantar surface (50 µL) of the left hind paw of rats [48] . Compounds were administered at 10 mg/kg i.v. 24 h after CFA injection. The mechanical allodynia was monitored 24 h after CFA injection and up to 4 h after administering the compounds. Paw withdrawal latency to mechanical stimulation was assessed with an automated testing device consisting of a steel rod that is pushed against the plantar surface of the paw with increasing force until the paw is withdrawn (Dynamic Plantar Aesthesiometer; Ugo Basile). The maximum force was set at 50 g to prevent tissue damage and the ramp speed was 2.5 g/s. Rats were placed in test cages with a metal grid bottom. They were kept in the test cages for 30-40 min to allow accommodation. The paw withdrawal latency was obtained as the mean of 3 consecutive assessments at each time point (at least 10 s between repeated measurements of the same paw).
 Oxygen Radical Absorbance Capacity (ORAC) Experiment. The ORAC assay was performed following Ou et al. [49] , as modified by Davalos et al. [44] . All samples and reagents were dissolved in phosphate buffer (75 mM; pH 7.4). The reaction was performed in a final volume of 200 μl: 20 μl test samples or 20 μl Trolox solutions (0.2 -2 nM), 120 μl fluorescein solution (1.17 mM) and 60 μl 2,2'-azobis-(2-methylpropionamidine) dihydrochloride (AAPH) 1.3% solution (all from Sigma Aldrich) were added to the wells of a black 96-well plate. The fluorescence was recorded at 40 °C every 55 s for 95 min using a fluorimeter (SpectraMax M2; Molecular Devices, California, USA), with excitation and emission wavelengths of 480 and 520 nm, respectively. All samples were tested in triplicate. ORAC values were expressed as μmol Trolox equivalents/ μmol of pure compound.
Conclusion
A series of 1,3-diphenylpropan-1-ones have been synthesized and evaluated for their activity at α7 nAChRs. Remarkably, the modulation of these nicotinic channels goes in opposite directions depending on the phenyl ring substituents. Thus, while OMesubstituted derivatives inhibited the activation of α7 nAChRs by ACh (probably acting as NAMs), most analogues with OH substitutions are type I PAMs. Compounds 7 and 31 display the best potency and efficacy profiles within the series, and the latter is highly selective against α3β4 and α4β2 nAChRs. In in vivo experiments, using an inflammatory pain model of mechanical hyperalgesia, compound 31 showed significant antinociceptive effects, comparable to that displayed by PNU-120596, while the tetrahydroxy analogue 7 was inactive. The about 10-fold lower permeability of compound 7, compared to 31, could explain its lack of activity in the in vivo test. In addition to the above indicated in vitro and in vivo activities, these compounds displayed remarkable antioxidant properties in ORAC experiments. Compounds within this 1,3-diphenylpropan-1-one series could serve to restore the impaired sensory gating and cognitive deficits in AD, because of their cholinergic connection. Also by reason of the fact that oxidative stress and plaque deposition, associated with chronic inflammation in the brain, are key events in AD pathogenesis and progression. The multiactivity and pharmacokinetic profile of compound 31 could place it as a good starting point to improved analogues having potential longer advance in the course of the drug development process. Work in this direction is underway in our labs.
Future perspective
Alpha7 nicotinic acetylcholine receptor (α7 nAChR) is an important player of the cholinergic nerve system in the brain, associated with the anti-inflammatory pathway of the parasympathetic nervous system. Experimental models indicated that vagal nerve stimulation attenuates the production of proinflammatory cytokines, inhibiting the inflammatory process, probably through the α7 nAChRs. This provides a rationale for the utility of α7 nAChR agonists and PAMs in the treatment of inflammatory pain. Both central and peripheral α7nAChR has been involved in changes in body weight associated to nicotine. As important peripheral mediators of chronic inflammation, α7nAChRs are also key contributors to obesity. Recent studies identify links between α7nAChR expression and obesity, insulin resistance, and diabetes. Therefore, this nicotinic channel may also be a useful therapeutic target to treat and manage obesity. In addition, the reduction of the α7 nAChR function has been identified as a potential mechanism for elevated tobacco consumption and consequently, the activation of α7 nAChRs could be explored for tobacco cessation therapy. The α7-nAChR receptors are expressed by macrophages and its expression is crucial for the anti-inflammatory effect of vagal nerve signaling. Nicotine exerts antiinflammatory effects on macrophages that can be counteracted by selective α7-antagonists. [50, 51] Selective α7 nAChR agonists have proven effective in reducing macrophage cytokine production and inflammation in animal models of pancreatitis, [52] dextran sulfate sodium (DSS)-induced colitis [53] and intestinal ileus. [54] Nicotine has been tested in clinical trials as a treatment for inflammatory diseases such as ulcerative colitis, but the therapeutic potential of this mechanism is limited by the collateral toxicity of nicotine, which support the needed of designing new molecules as positive allosteric modulators of α7 nAChR that would have antiinflammatory effects while eluding collateral toxicity. Finally, α7 nicotinic channels are also implicated in the modulation of different cognitive functions such as attention, and working and episodic memory. Increasing preclinical and clinical evidences suggest that α7 nAChR activation is of promising therapeutic value for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. Nowadays, there are no approved drugs that work through this receptor subtype, although several are at different stages of clinical development. Recent promising approaches are based on the use of positive allosteric modulators, PAMs, due to their several advantages over direct agonists. However, their effects, regarding inflammatory pain, nicotine dependence, obesity and cognitive functions during neurodegenerative diseases, have not been totally characterized. The present findings confirm and extend the observations indicating that the positive allosteric modulation of α7-nAChRs displays antinociceptive effects in models of inflammatory pain. The antioxidant activity of our compounds could represent an additional advantage for studying their potential applications to diseases triggered by multiple mechanisms, like obesity and AD. All the information that is being generated by preclinical and clinical studies on this subject will provide a deeper understanding of the nicotinic pathway in the indicated pathological conditions, and could result in new α7 nAChR-targeted therapies for treating them.
Supplementary data Synthetic experimental procedures and characterization of new compounds. Activities of compounds 7 and 31 at other nAChRs.
Executive summary  The allosteric modulation of α7 nAChRs represents promising therapeutic strategies for the treatment of inflammatory pain, and cognitive impairments, among other pathological conditions.
 OMe-substituted 1,3-diphenylpropan-1-ones are able to inhibit the activation of α7 nAChRs.
 Hydroxy-substituted 1,3-diphenylpropan-1-one analogues are potent and selective α7 nAChR positive allosteric modulators.
 Compound 31 behaves as a potent and selective α7 nAChR PAM and displays antinociceptive activity in an inflammatory pain model.
 Its antioxidant activity, combined with the properties at the nicotinic pathway, predict future potential for multimechanism-triggered diseases, like obesity and AD. The diagram shows the paw withdrawal latencies in response to mechanical stimulation (n ≥ 6 rats/group). Data are given as mean ± SEM n = 6. 2-Way ANOVA with Bonferroni post hoc test. *P <0.05; **P <0.01, ***P <0.001. 
